Description:
CYSTINOSIS, LATE-ONSET JUVENILE OR ADOLESCENT NEPHROPATHIC TYPE
Repository
|
NIGMS Human Genetic Cell Repository
|
Subcollection |
Heritable Diseases Lysosomal Storage Diseases |
Class |
Disorders of Amino Acid Metabolism |
Cell Type
|
Fibroblast
|
Transformant
|
Untransformed
|
Race
|
White
|
Family Member
|
4
|
Relation to Proband
|
mother
|
Confirmation
|
Clinical summary/Case history
|
Species
|
Homo sapiens
|
Common Name
|
Human
|
Remarks
|
|
Passage Frozen |
15 |
|
IDENTIFICATION OF SPECIES OF ORIGIN |
Species of Origin Confirmed by Nucleoside Phosphorylase Isoenzyme Electrophoresis |
|
Gene |
CTNS |
Chromosomal Location |
17p13 |
Allelic Variant 1 |
exon 11 skipped; CYSTINOSIS, LATE-ONSET JUVENILE OR ADOLESCENT NEPHROPATHIC TYPE |
Identified Mutation |
IVS11+2,T>C |
Remarks |
Clinically unaffected mother of two affected children, GM00378 and GM00379; heterozygote level of 1/2 cystine in white cells; results from targeted next generation sequencing using human genome version hg19 and confirmation by Sanger sequencing indicate that allele 1 has a splice site mutation at the +2 position of exon 11 [IVS11+2 T>C] or c.970+2T>C, Zykovich et al. Molecular Genetics and Metabolism Reports 5 (2015) 63-66.9 |
Zykovich A, Kinkade R, Royal G, Zankel T, Molecular genetics and metabolism reports5:63-66 2015 |
PubMed ID: 28649545 |
|
Thoene J, Lemons R, Anikster Y, Mullet J, Paelicke K, Lucero C, Gahl W, Schneider J, Shu SG, Campbell HT, Mutations of CTNS causing intermediate cystinosis. Mol Genet Metab67(4):283-93 1999 |
PubMed ID: 10444339 |
|
Langman CB, Moore ES, Thoene JG, Schneider JA, Renal failure in a sibship with late-onset cystinosis. J Pediatr107:755-6 1985 |
PubMed ID: 4056976 |
Passage Frozen |
15 |
Split Ratio |
1:3 |
Temperature |
37 C |
Percent CO2 |
5% |
Medium |
Eagle's Minimum Essential Medium with Earle's salts and non-essential amino acids with 2mM L-glutamine or equivalent |
Serum |
15% fetal bovine serum Not inactivated |
Substrate |
None specified |
Subcultivation Method |
trypsin-EDTA |
Supplement |
- |
|
|